Information updates

Product supply update – danazol

28 February 2020

Danazol is used in some patients for the management of hereditary angioedema (HAE). Danazol (Azol) has recently been discontinued (in January 2020) in Australia by the supplier (Mylan, formerly Alphapharm), as reported on the TGA website  Other brands of danazol may be sourced using a Special Access Scheme (SAS) application to the TGA. Please refer below for further information.  In New Zealand danazol is still available from Mylan.  

For patients who will no longer be prescribed danazol, ASCIA recommends that they should gradually run down supplies and not stop suddenly, as this could result in increased HAE attacks. For example, they may half their usual dose until supply is finished.

All patients with HAE should have adequate supplies of Icatibant (Firazyr®) on hand, and if possible they should keep a written diary of HAE attacks for at least a month, as they may qualify for Berinert® SC.  

Access to other brands of danazol in Australia

The Therapeutic Goods legislation provides a number of avenues through which Australian residents and medical practitioners may access therapeutic goods which are not registered in Australia. One of these avenues is the Special Access Scheme (SAS), which refers to arrangements to allow for the import and/or supply of an unapproved therapeutic good for a single patient, on a case by case basis. To access unapproved danazol  via the SAS, a patient’s doctor can submit an application to the TGA. Further information regarding the SAS and the relevant application forms are available from the TGA website: Should the doctor have enquiries regarding the SAS, the doctor can email This email address is being protected from spambots. You need JavaScript enabled to view it..

As these products are not approved for marketing in Australia, the TGA is unable to vouch for the quality, safety or efficacy of unapproved products. Suppliers (sponsors) who have advised that they may be able to bring in danazol products under SAS are:

  • Medsurge Healthcare Pty Ltd – Ph: 1300 788 261
  • Link Medical Products Pty Ltd – 1800 181 060
  • HL Pharma Pty Ltd – 03 9823 6228

There may be other suppliers who can also supply danazol under SAS.


Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.